This study sought to assess the impact of continuous flow left ventricular assist devices (LVADs) on functional capacity and heart failure-related quality of life.
Left ventricular assist devices (LVADs) are becoming a standard therapeutic option for patients with advanced heart failure who are failing maximal medical treatment (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) . Newer generation LVADs have been developed with continuous flow, rotary pump technology and are smaller and quieter than older pulsatile volume displacement LVADs, with the capability of providing similar outputs of up to 10 l/min (9 -11) . Continuous flow LVADs have been demonstrated to improve morbidity and mortality in critically ill patients awaiting transplantation while simultaneously reducing adverse events (9 -11) .
Previous studies on pulsatile flow LVADs have demonstrated significant improvements in quality of life measures and New York Heart Association (NYHA) functional class over time (5, (13) (14) (15) (16) (17) . Initial results from the continuous flow HeartMate II LVAD (Thoratec Corporation, Pleasanton, California) trials also indicate improvements in quality of life and functional status (9 -11,18 ) and stability or improvements in domains of neurocognitive function (19) . However, a detailed analysis in a large number of patients that describes the impact of continuous blood flow with reduced pulse pressure on long-term patient exercise performance and quality of life metrics has not been performed. In this study, we report the impact of a continuous flow LVAD in over 650 patients with advanced heart failure on quality of life and functional capacity for up to 24 months of circulatory support.
Methods
The HeartMate II LVAD is a continuous flow device consisting of an internal axial-flow blood pump with a percutaneous lead that connects the pump to an external system controller and power source (Fig. 1) . Data presented in this analysis are from the HeartMate II bridge to transplant (BTT) and destination therapy (DT) clinical trials that were conducted between 2005 and 2009 at 38 centers in the U.S. (9 -11) . The authors had access to the primary data and attest to its accuracy. The HeartMate II studies were conducted in compliance with U.S. Food and Drug Administration (FDA) regulations for good clinical practices. The protocols were approved by the FDA and each participating center's institutional review board.
Study subjects. Patients enrolled in the BTT trial had NYHA functional class IV heart failure symptoms and were listed as high priority for transplantation (United Network for Organ Sharing status 1A or 1B). Patients with NYHA functional classes IIIB and IV heart failure who were ineligible for heart transplantation and refractory to optimal medical management were considered for enrollment in the DT trial. Exclusion criteria for both the trials included severe renal, pulmonary, or hepatic dysfunction, active uncontrolled infection, a mechanical aortic valve, aortic insufficiency, an aortic aneurysm, other mechanical circulatory support (except an intra-aortic balloon pump [IABP]), and technical obstacles thought by the investigator to pose excessive surgical risk. Detailed characteristics and inclusion/exclusion criteria of each of these patient cohorts have been published elsewhere (9 -11). All participating patients provided written informed consent. Baseline and post-implant assessments. Assessments of functional status and quality of life were obtained in patients prior to LVAD implant (baseline) and at 1, 3, and 6 months post-implant for those enrolled in the BTT trial, and at 1, 3, 6, 12, 18, and 24 months for patients in the DT trial. ALT ϭ alanine aminotransferase; BP ϭ blood pressure; BTT ϭ bridge to transport; BUN ϭ blood urea nitrogen; CI ϭ cardiac index; CRT ϭ cardiac resynchronization therapy; DT ϭ destination therapy; IABP ϭ intra-aortic balloon pump; LVEF ϭ left ventricular ejection fraction; Na ϭ serum sodium; PCWP ϭ pulmonary capillary wedge pressure. NYHA functional class at each time period was assessed independently by a physician, nurse, or other trained medical staff not directly involved with the patient's care at that time. Submaximal exercise performance was measured using the 6-min walk test. Patients unable to walk at any time period due to a medical condition (i.e., IABP in place; in intensive care unit on inotropes; orthopedic limitations) and patients who refused to walk were excluded from this analysis.
Activity levels were assessed using metabolic equivalent task score (METs) in which patients were asked to describe their highest activity level during the reporting period, with scores ranging from very low (Ͻ1 METS ϭ bedridden, unable to care for self, unable to participate in any physical activity), moderate (2 to 4 METS ϭ walking 2 to 3 mph, light gardening, vacuuming or mopping the floor, golfing, painting walls), to very high (Ͼ6 METS ϭ dancing, climbing stairs, stationary cycling [Ͼ10 mph], heavy shoveling) (20) .
Heart failure-related quality of life was assessed with the Minnesota Living With Heart Failure Questionnaire (MLWHF) (21, 22) and Kansas City Cardiomyopathy Questionnaire (KCCQ) (23) . The MLWHF questionnaire assesses the impact of heart failure and its treatment on key physical, emotional, social, and mental dimensions of quality of life. The KCCQ quantifies physical function, symptoms (frequency, severity, and recent change), social function, self-efficacy, and knowledge, and quality of life. An overall summary score (OSS) is derived by combining scores in each domain. A clinical summary score (CSS) is derived by combining the physical function and symptoms scores. For both KCCQ summary scores, a higher value represents Figure 2 Changes in Functional Class Following LVAD New York Heart Association (NYHA) functional class was determined by an independent clinician at the time points shown in the bridge to transplant (BTT) and destination therapy (DT) trials. Study inclusion criteria required NYHA functional class III to IV symptoms at baseline. NYHA functional class improvements were statistically significant in both trials (p Ͻ 0.001). (24) .
Results
Baseline clinical characteristics of patients are shown in Table 1 . The BTT patients were younger and more likely to be treated with intravenous inotropic agents or an IABP, whereas the DT patients had a higher systolic blood pressure and worse renal function. More than 75% of patients in both groups were receiving intravenous inotropes at baseline, and 45% of patients in the BTT and 21% in the DT trials were supported with an IABP at study enrollment. Cardiac resynchronization therapy (CRT) was used in 48% and 72% of the BT and DT patients, respectively. The number of patients available for testing varied at each time interval because of transplantation, death, study withdrawal, device explantation, availability of study personnel, and scheduling. Overall survival and outcomes associated with the BTT and DT trials have been published previously (9 -11). Functional status. NYHA FUNCTIONAL CLASS. Figure 2 shows the change in NYHA functional class over time for the BTT and DT cohorts. At baseline, most patients had NYHA functional class IV symptoms, and after 1 month of support, 59% (BTT) and 47% (DT) of patients improved to NYHA class I or II, increasing further after 6 months of support to 82% (BTT) and 80% (DT). Approximately 80% of DT patients remained in NYHA functional class I or II from 6 through 24 months. With respect to their baseline scores, patients achieved highly significant improvement in NYHA functional class at all study intervals for both the study groups (p Ͻ 0.001). There was no significant difference in the improvements seen in NYHA class between BTT and DT patients.
6-MIN WALK TEST.
At baseline, a relatively small percentage of patients in both the BTT (14%) and DT (34%) cohorts were able to perform the 6-min walk test. For patients who performed the test, average baseline 6-min walk distance was 214 Ϯ 125 m (BTT) and 204 Ϯ 150 m (DT), which increased significantly at 6 months to 372 Ϯ (Fig. 3) . The 6-min walk distance was maintained throughout the follow-up period in the DT patients and was 360 Ϯ 210 m at 24 months. Overall, there was a statistically significant improvement over time at all test intervals for both study groups (Fig. 3) . In DT patients, the mean walk distance from baseline to 24 months increased by more than 150 m.
PATIENT ACTIVITY SCORES. Figure 4 shows the percentage of patients with each activity level at each time point. At baseline, 93% of patients in the BTT group, and 96% of the patients in the DT group described their level of activity as either low or very low. By 6 months, 68% of patients in the BTT group and 62% in the DT group described their activity levels as moderate, high, or very high, an improvement that was highly significant (p Ͻ 0.001). After 6 months, the level of improvement stabilized in the DT cohort, and 60% of the patients described their activity levels as moderate, high, or very high at 24 months.
QUALITY OF LIFE QUESTIONNAIRES. MLWHF scores decreased over time, indicating an improvement in quality of life (Fig. 5 , Table 2 ). When compared with baseline scores in patients with paired comparisons, highly significant (p Ͻ 0.001) median improvement in scores of Ϫ10 and Ϫ13 points were seen at 1 month in the BTT and DT groups, followed by continued improvements of Ϫ29 and Ϫ40 points at 6 months of support. The median percent improvement at 6 months for the BTT and DT groups were 38% and 52%, respectively. At 24 months, there was a median improvement of Ϫ42 points (55%) compared with baseline. KCCQ overall summary and clinical summary scores also improved during HeartMate II support (Fig. 6, Table 2 ). The median KCCQ OSS showed significant early improvements by 14 and 16 points at month 1 for BTT and DT patients compared with baseline, with 28 and 39 point improvements at 6 months of support. After 6 months, the KCCQ scores remained stable with a median improvement in DT patients of 41 points at 24 months compared with baseline. Similar improvements were observed in the KCCQ CSS. At 6 months post-implant, 79% of BTT and 92% of DT patients with paired data had achieved a clinically meaningful improvement of Ͼ5 points in their KCCQ OSS compared with baseline. Similar results were found for the KCCQ CSS.
Discussion
The current study demonstrates that patients with advanced heart failure who have marked functional limitations and impaired quality of life derive significant improvements in submaximal exercise performance and heart failure-related quality of life following implantation of a continuous flow LVAD. Similar improvements were seen in both the BTT and DT patients, 2 overlapping populations typically defined by age and severity of comorbidities. Although trial 
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Quality of Life With Continuous Flow LVAD design limited follow-up to 6 months in the BTT cohort, the DT trial allowed more prolonged observation of changes in patient functionality and quality of life. The early improvements in exercise performance and quality of life demonstrated in both patient groups were sustained and showed no evidence of decline through 2-year follow-up. The current report is the largest study of advanced heart failure patients with serial measurement of functional capacity and quality of life metrics following a mechanical intervention. The poor pre-implant exercise performance and quality of life scores despite optimal medical and electrical therapies, including CRT when appropriate, highlight the limitations of currently utilized treatments for patients with stage D heart failure. Recent studies have documented 1-year survival rates of 73% in BTT patients (10) and 1-and 2-year survival rates of 68% and 58% in DT patients supported with a continuous flow LVAD (11) . However, a majority of patients with advanced heart failure express a strong desire for improvements in quality of life and functionality, even at the expense of longevity (25, 26) . The totality of data from the HeartMate II trials suggests that these patients who have a predictably high short-term mortality and symptoms with minimal activity or at rest may be able to achieve both mortality reduction and improved quality of life following treatment with a continuous flow LVAD. Therapies targeted to the stage D heart failure population must focus on patient-centric outcomes that include reduction of symptom burden and improved ability to perform the activities of daily living. This study establishes a benchmark against which other medical and device therapies can compare.
The 6-min walk test is an accepted method for assessing functional capacity that has good reproducibility, is well tolerated, and is very relevant to daily activities (27) . This test has been used extensively in heart failure clinical trials (28) . The relative improvements in exercise performance seen with the continuous flow LVAD can be put into perspective by comparison to the outcomes of patients enrolled in CRT trials. A prior study supporting the use of CRT in patients with NYHA functional class III to IV heart failure symptoms established that a 39-m improvement in 6-min walk distance can be considered clinically meaningful (29) . A retrospective analysis of patients with NYHA functional class IV symptoms treated with CRT from the COMPANION (Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure) trial demonstrated a statistically significant 46-m increase in 6-min walk distance with 78% experiencing Ն1 functional class improvement (30) . In contrast, LVAD-treated patients in this study who were able to complete a 6-min walk test prior to device implantation had a 146-m increase in mean walk distance at 6 months (DT group), and more than 80% of patients had Ն2 functional class improvements (DT group). Additionally, most patients reported significant increases in daily functional capabilities as indicated by moderate activity levels or higher based upon estimated METs. Values are the mean Ϯ SD and median [25th, 75th percentiles] of paired changes at each time point compared with baseline. Also shown are the percent improvements of the median from baseline. CSS ϭ clinical summary score; HMII ϭ HeartMate II; KCCQ ϭ Kansas City Cardiomyopathy Questionnaire; MLWHF ϭ Minnesota Living With Heart Failure; OSS ϭ overall summary score.
